NCT05099666 2026-04-13
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Massachusetts General Hospital
Phase 1/2 Active not recruiting
Clinical Trials
13 trialsNCT05918640 2026-03-31
LiFFT
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT04802174 2026-03-17
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT06681220 2026-03-11
Relapsed SCLC
VA Office of Research and Development
Phase 1/2 Recruiting
NCT05734066 2026-02-03
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Jazz Pharmaceuticals
Phase 1/2 Recruiting
NCT07153055 2025-12-18
LOTS
Indiana University
Phase 1/2 Not yet recruiting
NCT07141771 2025-08-26
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Not yet recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04358237 2025-06-04
LUPER
Blanco, Dr Antonio Calles MD
Phase 1/2 Completed
NCT06385548 2025-04-01
LiDer
Vall d'Hebron Institute of Oncology
Phase 1/2 Withdrawn
NCT04253145 2023-11-18
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
Fundacion Oncosur
Phase 1/2 Unknown
NCT05042934 2022-02-10
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02684318 2017-06-22
Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Poveda, Andrés, M.D.
Phase 1/2 Unknown